Clinical Trials Logo

Clinical Trial Summary

This phase II trial studies the side effects of erlotinib hydrochloride and how well it works in reducing duodenal polyp burden in patients with familial adenomatous polyposis at risk of developing colon cancer. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.


Clinical Trial Description

PRIMARY OBJECTIVES: I. To assess the mean percent change in duodenal polyp burden (sum of diameters from all polyps) from baseline to 6 months post-intervention for familial adenomatous polyposis (FAP) subjects receiving weekly erlotinib hydrochloride (erlotinib). II. To assess the grade 2/3 adverse event rate in this population and compare it to historical data. SECONDARY OBJECTIVES: I. To evaluate all adverse events at least possibly attributed to weekly erlotinib. II. To assess the absolute and percent change in duodenal polyp number from baseline to 6 months. III. To assess the absolute and percent changes in lower gastrointestinal polyp burden and number for the subset of participants with ileal pouch anal anastomosis (IPAA) or ileo-rectal anastomosis with rectal stump. IV. To assess the absolute and percent change in desmoid tumor size in participants who have baseline and follow up computed tomography (CT)s performed as part of their standard of care. CORRELATIVE OBJECTIVES: I. Gene expression profiles in duodenal adenomas and uninvolved tissue will be compared between baseline and endpoint samples using negative binomial statistics (DESeq2). II. Identify differentially expressed genes between duodenal polyps and uninvolved tissue at endpoint compared to baseline. III. Evaluate the effect of weekly erlotinib on EGFR and Wnt target gene expression in duodenal adenomas. IV. Evaluate the effect of weekly erlotinib on immune response signaling in duodenal adenomas and uninvolved tissue. OUTLINE: Patients receive erlotinib hydrochloride orally (PO) once weekly. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02961374
Study type Interventional
Source National Cancer Institute (NCI)
Contact
Status Completed
Phase Phase 2
Start date October 27, 2017
Completion date September 27, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT05223036 - Testing Obeticholic Acid for Familial Adenomatous Polyposis Phase 2
Completed NCT01483144 - Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP) Phase 3
Completed NCT00641147 - Curcumin in Treating Patients With Familial Adenomatous Polyposis Phase 2
Recruiting NCT03471403 - Cold Snare Polypectomy for Duodenal Adenomas in Familial Adenomatous Polyposis
Not yet recruiting NCT04531930 - Colorectal Adenoma Canceration in FAP
Recruiting NCT04678011 - A Personalized Surveillance and Intervention Protocol for Patients With Familial Adenomatous Polyposis That Have Undergone (Procto)Colectomy
Recruiting NCT04677998 - A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis
Completed NCT00927485 - Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP) N/A
Recruiting NCT00253812 - Adenoma Detection Rate:NBI, AFI, Chromoscopic or Standard Endoscopy N/A
Withdrawn NCT00248053 - Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis Patients Phase 2
Recruiting NCT02012699 - Integrated Cancer Repository for Cancer Research
Completed NCT04674228 - Review of Post-Study Clinical Endoscopy Reports in Follow Up to MAY2016-07-01
Completed NCT01656746 - Single Incision Laparoscopic Surgery in Treating Patients With Colorectal Disease N/A
Completed NCT00808743 - Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis Phase 2/Phase 3
Active, not recruiting NCT03847636 - CryoBalloon Ablation for Treatment of Duodenal Adenomas N/A
Not yet recruiting NCT05112822 - Testing Obeticholic Acid (OCA) for Familial Adenomatous Polyposis (FAP) Phase 1
Recruiting NCT02656134 - Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis (FAP) N/A
Withdrawn NCT01245816 - A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP) Phase 3
Not yet recruiting NCT05630794 - Testing ONC201 to Prevent Colorectal Cancer Phase 1
Recruiting NCT04709445 - Perfusion Rate Assessment by Near-infrared Fluorescence in Gastrointestinal Anastomoses N/A